Omeros Shares Fall After BofA Downgrade
12:59PM ET 6/08/2022 MT NewswiresOmeros (OMER) shares are down nearly 11% in early afternoon trading after the biopharmaceutical company's stock was downgraded by BofA Securities. The firm...
Omeros (OMER) shares are down nearly 11% in early afternoon trading after the biopharmaceutical company's stock was downgraded by BofA Securities. The firm...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...
Omeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...
Address | The Omeros Building Seattle, Washington 98119 |
Phone | +1 206 676-5000 |
Number of Employees | 236 |
Recent SEC Filing | 06/24/2022![]() |
Chairman, President & Chief Executive Officer | Gregory A. Demopulos |
Chief Financial Officer, Treasurer & VP | Michael A. Jacobsen |
Chief Scientific Officer & Vice President-Science | George A. Gaitanaris |
Chief Medical Officer & Vice President | J. Steven Whitaker |
Price Open | $2.80 |
Previous Close | $2.75 |
52 Week Range | $1.86 - 16.57 |
Market Capitalization | $291.1 M |
Shares Outstanding | 62.7 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/08/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | 1.48 |
Earnings per Share | -$1.75 |
Beta vs. S&P 500 | N/A |
Revenue | $29.9 M |
Net Profit Margin | -234.76% |
Return on Equity | 112.70% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |